HARMONY Alliance develops Core Outcome Sets for blood cancers. ...
HARMONY wishes you all the best for 2021
PRESS RELEASE: ASH2020: New data from HARMONY demonstrate
HARMONY KOLs Bullinger and D'Agostino presenting at ASH2020.
HARMONY iposter at ISPOR2020
Press Release: Launching HARMONY PLUS
IMI showcases HARMONY’s efforts in managing COVID-19
Oncology Times publishes news feature on HARMONY
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands